Drospirenone vs Oseltamivir: side-by-side comparison
Drospirenone (Progestogen with anti-mineralocorticoid and anti-androgen activity) and Oseltamivir (Neuraminidase inhibitor) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Drospirenone | Oseltamivir |
|---|---|---|
| Therapeutic class | Progestogen with anti-mineralocorticoid and anti-androgen activity | Neuraminidase inhibitor |
| CAS | 67392-87-4 | 196618-13-0 |
| ATC | G03AA12 | J05AH02 |
| Molecular weight | 366.49 g/mol | 312.40 g/mol |
| Brands with this active ingredient | 2 | 1 |
What they share
Drospirenone and Oseltamivir share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Drospirenone acts by a different mechanism than Oseltamivir, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Drospirenone: Drospirenone activates progesterone receptors to suppress ovulation and produce the contraceptive effect when combined with an estrogen. Oseltamivir: Oseltamivir is a prodrug rapidly hydrolysed by hepatic esterases to the active metabolite oseltamivir carboxylate, which selectively inhibits the neuraminidase enzyme on the surface of influenza A and B viruses.
Indications compared
Drospirenone: Drospirenone in combination with ethinylestradiol is approved as combined oral contraception, treatment of moderate acne in women requesting contraception, and treatment of premenstrual dysphoric disorder. Oseltamivir: Oseltamivir is approved in adults and children for the treatment of acute uncomplicated influenza A and B when started within 48 hours of symptom onset, and for post-exposure prophylaxis of influenza A and B in patients…
Safety profile
Drospirenone: Common adverse effects include menstrual irregularities, breast tenderness, headache, mood changes and nausea, mostly in the first 2–3 cycles. Oseltamivir: Common adverse effects include nausea and vomiting, particularly when taken without food.
Frequently asked questions
Is Drospirenone better than Oseltamivir? ▾
Drospirenone and Oseltamivir are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Drospirenone and Oseltamivir be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Drospirenone
Products with Oseltamivir
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.